Back to top
more

AC Immune (ACIU)

(Real Time Quote from BATS)

$2.32 USD

2.32
122,551

+0.20 (9.43%)

Updated Aug 4, 2025 02:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Earnings Preview: Qiagen (QGEN) Q3 Earnings Expected to Decline

by Zacks Equity Research

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

AC Immune (ACIU) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

NeoGenomics (NEO) Soars 8.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

NeoGenomics (NEO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

AC Immune (ACIU) Surges 43% in the Past 3 Months: Here's Why

by Zacks Equity Research

AC Immune's (ACIU) shares rose 43% over the past three months, driven by rapid progress in the development of its pipeline candidate, ACI-24.060, for neurodegenerative diseases.

Zacks Equity Research

AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance

by Zacks Equity Research

Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.

Zacks Equity Research

AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of 29.17% and 457.95%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen

by Kinjel Shah

Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.

Zacks Equity Research

AC Immune (ACIU) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of 17.24% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline

by Zacks Equity Research

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Biogen (BIIB) Seeks Approval for Another Alzheimer's Candidate

by Zacks Equity Research

Biogen (BIIB) and partner Eisai start rolling submission of a regulatory filing seeking approval for lecanemab (BAN2401) as a potential approval for early Alzheimer's disease.

Zacks Equity Research

AC Immune's (ACIU) Stock Up Despite Mixed Data From AD Study

by Zacks Equity Research

AC Immune's (ACIU) candidate for mild-to-moderate AD meets one of the two co-primary endpoints. Resultantly, the stock price rises 16%

Zacks Equity Research

Biotech Stock Roundup: REGN Gives Study Update, INCY Wins Drug Approval & More

by Zacks Equity Research

Regulatory and pipeline updates from Regeneron (REGN) and Incyte (INCY), among others, have been in focus in the biotech industry over the past week.

Zacks Equity Research

AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of -31.82% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: AC Immune (ACIU) Q2 Earnings Expected to Decline

by Zacks Equity Research

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

AC Immune (ACIU) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of -19.05% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AC Immune (ACIU) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Biotech Stock Roundup: REGN's Drug Approval & Pipeline Updates From AMGN, BLUE

by Zacks Equity Research

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Amgen (AMGN) and bluebird (BLUE).

Zacks Equity Research

AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of -16.67% and 32.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline

by Zacks Equity Research

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

AC Immune's Candidate Fails in Alzheimer's Disease Study

by Zacks Equity Research

The failure of AC Immune's (ACIU) study on Alzheimer's disease brings this challenging but promising space in focus.

Zacks Equity Research

Do Options Traders Know Something About AC Immune (ACIU) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to AC Immune (ACIU) stock based on the movements in the options market lately.

Zacks Equity Research

Amicus' (FOLD) Q2 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Amicus (FOLD) posts a narrower-than-expected loss, while sales beat estimates in the second quarter of 2020.

Zacks Equity Research

Aerie (AERI) Q2 Earnings Miss Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Aerie (AERI) posts a wider-than-expected loss and sales miss estimates in the second quarter of 2020.